key: cord-0856060-wrj4ux51
authors: Shaldzhyan, Aram; Zabrodskaya, Yana; Yolshin, Nikita; Kudling, Tatiana; Lozhkov, Alexey; Plotnikova, Marina; Ramsay, Edward; Taraskin, Aleksandr; Nekrasov, Peter; Grudinin, Mikhail; Vasin, Andrey
title: Clean and folded: Production of active, high quality recombinant human interferon-λ1
date: 2021-09-02
journal: Process Biochem
DOI: 10.1016/j.procbio.2021.08.029
sha: b925b2dfdc58d926d61e2b499aa6fdd875be2c28
doc_id: 856060
cord_uid: wrj4ux51

Type III interferons exhibit antiviral activity against influenza viruses, coronaviruses, rotaviruses, and others. In addition, this type of interferon theoretically has therapeutic advantages, in comparison with type I interferons, due to its ability to activate a narrower group of genes in a relatively small group of target cells. Hence, it can elicit more targeted antiviral or immunomodulatory responses. Obtaining biologically-active interferon lambda (hIFN-λ(1)) is fraught with difficulties at the stage of expression in soluble form or, in the case of expression in the form of inclusion bodies, at the stage of refolding. In this work, hIFN-λ(1) was expressed in the form of inclusion bodies, and a simple, effective refolding method was developed. Efficient and scalable methods for chromatographic purification of recombinant hIFN-λ(1) were also developed. High-yield, high-purity product was obtained through optimization of several processes including: recombinant protein expression; metal affinity chromatography; cation exchange chromatography; and an intermediate protein refolding stage. The obtained protein was shown to feature expected specific biological activity in line with published effects: induction of MxA gene expression in A549 cells and antiviral activity against influenza A virus.

Interferons play a critical role in the immune response by suppressing viral spread in the early stages of infection and form the first line of defense against viral infection in mammals [1, 2] . According to amino acid sequence and type of receptor through which signal transduction is mediated, interferons are divided into three groups: types I, II, and III [1, 3] . Type III interferons (lambda interferons, IFN-λ) are related to type I interferons (interferon-α and interferon-β) and demonstrate a similar antiviral effect [4, 5] . Type III interferons are promising therapeutic agents that can induce a more targeted antiviral or immunomodulatory response than other interferon types [6, 7] . Such interferons primarily affect viruses that target cells of the respiratory tract, gastrointestinal tract, or liver [8] . Thus, type III interferons exhibit antiviral activity against a number of respiratory and gastrointestinal viruses: influenza virus; metapneumovirus; respiratory syncytial virus; coronavirus; and rotavirus [6] . Availability of a simple, effective method for producing type III interferons is a necessary prerequisite for further research of its potential as an antiviral or immunomodulatory agent. In previously published work, methods for production of recombinant hIFN-λ1 in soluble form with the proteolytically cleaved S-tag [9] , and in the form of inclusion bodies with 6His-tag [5, 10] , have been proposed.

Brady et al. [11] expressed wild-type and cysteine mutant versions of hIFN-λ1 in E. сoli in the form of inclusion bodies, followed by refolding by dilution and purification by cation exchange and hydrophobic interaction chromatography. Their method provided a higher yield per liter of culture medium, yet the wild-type hIFN-λ1 thus obtained had several disulfide isomers. Purification methods proposed by Xie et al. [12] , Magracheva et al. [13] , and Dellgren et al. [5] include a gel filtration step and are thus suitable for small-scale production due to limited scalability of the gel filtration method. a Nus-His-S-tag of 57.8kDa (NusA-S-His-tagged hIFN-λ1), followed by on-column tag cleavage by thrombin. In this work, we propose a method for expression of hIFN-λ1, bearing an N-terminal 6His-tag and without substitutions in the amino acid sequence of the protein, using a simple refolding procedure and scalable chromatographic purification methods.

The hIFN-λ1 produced features specific activity suitable for research and, potentially, future diagnostic or therapeutic application.

Reagents obtained from Sigma included: tris base; Na2HPO4; NaCl; EDTA; PMSF; Tween 20; glycerol; acetonitrile; TFA; trehalose; L-arginine; sodium acetate; acetic acid; HCl; and urea. HisTrap FF Crude and Source In the graphical abstract the structure 5T5W of hIFN-λ1 was used [14] .

In silico optimized sequence (https://www.genscript.com/tools/gensmart-codonoptimization), encoding hIFN-λ1 #Q8IU54 [15] , was synthesized by Evrogen and cloned into the pET302/NT-His plasmid. That vector contains a sequence encoding a polyhistidine tag at the N-terminus of synthesized protein. The resultant construct (pET302/NT-His-hIFN-λ1) was checked for errors by sequencing.

Escherichia coli cultures (BL-21 DE3) were transformed with pET302/NT-His-hIFN-λ1 and seeded on Luria Bertani (LB) agar plates containing ampicillin (100 μg/ml).

Individual colonies were picked and grown overnight in LB media (0.5% yeast extract, 1% Bacto tryptone, 1% NaCl) containing ampicillin. Overnight culture was then used to inoculate fresh LB medium containing ampicillin (OD600 = 0.1 at start of new incubation).

Bacterial cultures were grown in 2L culture flasks, containing 200 ml of antibioticselective LB medium, with agitation (orbital shaker) to an OD600 value of 0.7. To optimize cultivation conditions, protein expression was induced by various IPTG concentrations (0.5, 0.1, 0.01 mM), and cultures were incubated further (orbital shaker, 32°C or 37°C, 3 hours). Cultures were sonicated (MSE ultrasonic disintegrator) on ice J o u r n a l P r e -p r o o f (10 pulses, of 10 seconds each, in 30-second intervals), followed by centrifugation for 1 hour (20,000 g at +4°C). Supernatants and pellets were collected separately. Levels of hIFN-λ1 expression, and its presence in supernatants or pellets (inclusion bodies), were determined by polyacrylamide gel electrophoresis (SDS-PAGE).

Chromatographic purification was performed on a GE Healthcare AKTA pure 25M system. Primary purification of hIFN-λ1 was performed by immobilized metal affinity chromatography (IMAC) under denaturing conditions. Cells were centrifuged for 10 min at 4,500 g (+4°C). Next, cell pellets (1 g wet weight) were resuspended in 30 ml of denaturing buffer (20 mM sodium phosphate, 300 mM sodium chloride, 8 M urea, 20 mM imidazole, pH 7.8, 1 mM PMSF); suspensions were sonicated (MSE ultrasonic disintegrator) using 10 pulses (30 seconds each, at 2 minute intervals) on ice. Lysate was clarified by centrifugation for 20 minutes at 13,000 g ( + 10°C). Protein concentration was determined by the 'DC Protein Assay' (Bio-Rad, USA), based on the Lowry method. Lysozyme (Sigma, USA) was used as the standard protein to produce the calibration curve.

Purified protein was analyzed by SDS-PAGE using the Laemmli method under reducing conditions (with β-mercaptoethanol) and non-reducing conditions (without βmercaptoethanol) [16] . Electrophoresis materials used (Bio-Rad) included: 'Any kD TGX' precast gels; Kaleidoscope Plus Protein Ladder; PowerPac Basic DC power J o u r n a l P r e -p r o o f source; and Mini Protean Tetra cell. Gels were stained with a Coomassie soluti on as described [17] . Gels were visualized using the ChemiDoc MP gel documentation system and analyzed using Bio-Rad Image Lab Software.

Gel filtration analytical chromatography (GF) was performed on a Superdex 200 Increase 10/300 GL column (10 × 300 mm, GE Healthcare) with the Akta Pure 25 chromatographic system (GE Heathcare). Samples were diluted in phosphate-buffered saline to a final protein concentration of 0.1 mg/ml. The chromatographic column was washed with 50 ml of PBS at a flow rate of 1 ml/min. A mixture of standard proteins (ferritin -440 kDa, ovalbumin -44 kDa, ribonuclease A -13.7 kDa and aprotinin -6.5

Kit LMW, was used for column calibration. Injection volume was 50 ul for standard mix and sample. Elution was performed with phosphate-buffered saline at 1 ml/min at ambient temperature. Elution volume was 35 ml. The chromatogram was recorded at a wavelength of 280 nm. Based on the chromatogram of the standard (protein mixture), a calibration curve was fit, and the molecular weights of peaks were calculated.

ELISA was carried out using commercial reagents. Levels of hIFN-λ1 were evaluated by human IL-29/IL-28B (IFN-lambda 1/3) DuoSet ELISA (DY1598B, R&D Systems, USA), according to manufacturer's instructions. A different commercial kit, Mouse IL-28 A/B (IFN-lambda 2/3) DuoSet ELISA (DY1789B, R&D Systems), was used to assess cross-reactivity.

The amino acid sequence of recombinant 6xHis-hINF-λ1 protein was confirmed using MALDI-TOF mass spectrometry. Following PAGE, fragments were excised from gel and washed twice for dye removal (30 mM NH4HCO3 in 40% acetonitrile). Gel fragments were next dehydrated with 100% acetonitrile, dried in air, and subjected to enzymatic digestion by trypsin or chymotrypsin. Trypsin (20 ug/ml in 50 mM NH4HCO3) was added to gel, and incubation was performed for 2 hours at 60°C. Incubations with chymotrypsin (20 ug/ml in 100 mM Tris-HCl, 1 mM CaCl2, pH 8.0) were performed for 18 hours at 25°C. In both cases, reactions were stopped with 1% TFA in 10% acetonitrile. Peptides after enzymatic digestion were mixed with HCCA matrix, put onto the metal target, and their mass spectra recorded in positive ion registration reflective mode using the UltrafleXtreme MALDI-TOF mass spectrometer (Bruker). Spectra were processed in flexAnalysis software (Bruker). Protein identification was performed in BioTools (Bruker) using MASCOT (http://www.matrixscience.com/). It should be noted that: recombinant protein amino acid sequence ( Fig. 1b) was added to the local database; during the identification process, the two databases (local and SwissProt, https://www.uniprot.org/) were used simultaneously. Mass tolerance was established as 20 ppm; oxidation of methionine was indicated as a variable modification. Identification was considered reliable based on spectrum score and threshold (p < 0.05).

Type I and type III interferons induce the expression of ISGs (interferon stimulated genes) through their heterodimeric receptors. One of the key antiviral ISGs is MxA [3] . Unlike most ISGs, the Mx genes are not characterized by constitutive expression; their expression is specifically caused by the action of type I and III IFNs.

This makes MxA an excellent marker of activation of an IFN-dependent response [18] . 

Total RNA was isolated from A549 cells using TRIZol reagent according to manufacturer's instructions. RNA concentration and general integrity were measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, USA).

Following RNA extraction, samples were reverse transcribed using M-MLV reverse transcriptase (M-MLV RT) as described [19] . A mixture of 2 μg total RNA and 1 μg oligo(dT)16 primers, adjusted with ultrapure water to a final volume of 12 μl, was incubated at 70°C for 5 min. Tubes were immediately cooled on ice, and a mix was then hours after viral inoculation. Viral loads were evaluated by ELISA using in-house antibodies, as described [20] . 

Upon IPTG induction, a BL-21 DE3 cell culture transformed with the pET302/NT-His-hIFN-λ1 plasmid showed expression of a protein with a molecular weight of about 21 kDa. The theoretical molecular weight of the protein was 21.2 kDa. In the experiment, the concentration of inducer and the incubation temperature were varied. The incubation time with the inducer was 3 hours. Each sample was fractionated ( Figure   2a ).

Under the conditions tested, the target protein was expressed in the form of inclusion bodies. According to the literature [5, 10, 21] , this is a common occurrence with production of recombinant interferons in E. coli. It should be noted that the hIFN-λ1 gene was also cloned into the pET22b+vector, at the MscI and XhoI sites, in order to create a fusion protein not only with a histidine tag at the C-terminus, but also with pelB sequence at the N-terminus. The pelB sequence encodes a signal peptide, potentially contributing to periplasmic protein localization. However, even in the presence of the signal peptide, recombinant protein was localized in inclusion bodies (data not shown).

Since cultivation conditions and the presence of pelB sequence did not increase the amount of soluble protein, production of hIFN-λ1 was carried out using: pET302/NT-His plasmid; LB medium with ampicillin (100 μg/ml); 37°C incubation; and platform agitation (250 rpm). When the OD600 value reached 0.7, protein expression was induced by adding IPTG to a final concentration 0.01 mM, and cultivation with induction was continued for 3 more hours (Fig. 2b) . We have shown that expression of the protein initially occurs in the form of inclusion bodies, and thus problems with transition of the protein into an insoluble form during prolonged induction should not occur. Also, expression in the form of inclusion bodies, according to the available literature, at least partially protects the product from proteolytic degradation, and the host cells from possible toxicity of the product. Based on this, we decided to implement overnight induction to increase product yield.

Primary protein purification was carried out by metal affinity chromatography under denaturing conditions. This purification method, with on-column refolding of hIFN-λ1 described earlier [10] , showed low yield of refolded protein (less then 5 mg of correctly-folded protein per liter of culture). Therefore, it was decided to perform the first purification step under denaturing conditions, followed by refolding of the partially Two refolding buffers with different pH (Tris-HCl, pH 7.5; sodium acetate, pH 5.5), with and without refolding additives, were selected for screening. We used buffer J o u r n a l P r e -p r o o f systems, which have previously been shown to be effective (in our laboratory experience with recombinant proteins), as starting buffers for refolding. Arginine, glycerol, trehalose, and the non-ionic detergent Tween-20 are common agents used to protect protein from surface-induced aggregation during refolding. Two pH values were chosen because the ProtParam software does not take protein folding into account when calculating the isoelectric point.

Denatured recombinant protein samples (at a concentration of 2 mg/ml) were added to pre-cooled refolding buffer (to final concentration of 100 μg/ml) and mixed by pipetting, followed by incubation for 24 hours at + 4°C. Precipitated protein was removed by centrifugation for 1 hour at 20,000 g. Supernatants were collected and dialyzed against phosphate buffered saline for 24 hours, followed by filtration through a PES syringe filter (0.2 μm pore size). Protein concentrations were determined by the Lowry method. For estimation of relative 'soluble protein yield' of refolding variations, 100 μg/ml was designated as 100%. The results of the experiment are shown in Table 1 .

The highest yields of recombinant hIFN-λ1 in soluble form were seen with two specific refolding buffers: Buffer C (80%); and Buffer E (89%). The proposed refolding method provides a significantly higher yield, takes less time, and is more economical in comparison with the stepwise dialysis method proposed [5] for IFN-λ3, another type III interferon. Conductivity of the protein solution after refolding was about 5 mS/cm; therefore, it does not interfere with subsequent ion-exchange chromatography. There is thus no need for dialysis or diafiltration of the refolded protein solution. It is possible to proceed directly to the final purification step.

The isoelectric point of the hIFN-λ1 recombinant protein was 9.08 according to the ProtParam Tool [22] . Thus, hIFN-λ1 in refolding solution is positively charged, so cation exchange chromatography was chosen as a final purification step. With comparison of different cation exchange resins, the best results (maximum protein yield, J o u r n a l P r e -p r o o f minimal impurities) were noted (data not shown) with resins featuring particle size of 15 μm or less, such as Source 15S (GE Healthcare) and ENrich S (Bio-Rad). Source 15S was selected because of higher flow rates and availability for purchase in bulk (for potential process scale-up later). The chromatogram of the final protein purification step is shown in Figure 3b . The target protein eluted in the conductivity range from 45 to 65 mS/cm. It should be noted that hIFN-λ1, at room temperature, elutes as a double peak (Fig. 3b, solid red line) . This may indicate the presence of two different conformational variants or a simultaneous presence of monomer/dimer combinations. When elution was performed at +6ºC, a single peak of recombinant protein resulted (Fig. 3b, In order to compare the purification and refolding process developed here with methods described in the literature, we collected known data in Table 3 . Despite our significantly lower protein yield, in comparison with the method proposed by Brady et al. in 2004 [11] , our method provides a single protein isoform if purification is maintained at +6ºC during cation exchange chromatography. Among the advantages of our method is the use of scalable chromatographic purification methods (affinity and ion exchange chromatography), in comparison with the methods proposed in [5, 12, 13] (gel filtration has scale-up limitations). Further, we were unable to achieve reproducible results when using the on-column refolding method proposed in [10] .

The purity of the recombinant protein was analyzed by SDS-PAGE. Figure 3c shows all steps of target protein purification. The presence of a band with an electrophoretic mobility of about 21 kDa (indicated by an arrow) indicates selective isolation of the protein from the protein mixture present in the cell culture. It should be noted that under non-reducing conditions (Fig. 3c , 'IEC S-S'), a minor band (near the 37 kDa reference), likely representing dimers, is seen. This could be interpreted as a sample preparation artifact. Gel-filtration results indicate a predominance of the main form (mol. weight ~ 25 kDa, corresponding to hIFN-λ1 monomer), with the dimeric form associated fraction constituting less than 1.5%. Thus, it can be concluded that the resultant protein product consists predominantly of the monomeric hIFN-λ1 form (~ 98%).

Confirmation of recombinant protein amino acid sequence was carried out using MALDI-TOF mass spectrometry after enzymatic hydrolysis of 'protein in gel' with trypsin.

In the area marked with an arrow (Fig. 3с) , the 6xHis-hIFN-λ1 recombinant protein was reliably identified (Score/threshold was 156/76, sequence coverage 70%). Additional hydrolysis with chymotrypsin extends the sequence coverage to 85%. Protein sequences found in mass spectra are highlighted in Figure 1b . The registered ions and the corresponding peptides are presented in Table S1 . Thus, the obtained protein was reliably identified as human interferon lambda-1 (6xHis-hIFN-λ1).

Binding of the recombinant protein with anti-hIFNλ1 monoclonal antibodies was shown by sandwich ELISA. The commercial 'Human IL-29/IL-28B (IFN-lambda 1/3)

DuoSet ELISA' kit (DY1598B, R&D Systems) was used (Fig. 4) .

For each concentration, the average optical absorbance (OD450-OD655) is indicated in relative units. Concentrations of hIFN-λ1 were determined by the Lowry method. These results show that a constant +4°C temperature is the preferred storage condition for recombinant hIFN-λ1 protein, not -80°C followed by thawing. Increasing the stability of the protein product is a priority goal for further improvement of this method.

Ideally, this would minimize changes associated with one or more 'freeze-thaw' cycles.

In order to exclude the possibility of stimulation of A549 cells by bacterial lipopolysaccharides, the endotoxin level was determined by LAL test. The results show that recombinant hIFN-λ1 solution contains endotoxin at a concentration of about 25 EU/ml, which corresponds to no more than 5 ng/ml of endotoxin [23] . The concentration of the analyzed sample was 620 μg/ml. Consequently, there was less than 0.05 EU endotoxin per μg of protein, which is in line with commercial analogues on the market [24] . Thus, endotoxins present in the solution should not significantly affect the immune response of cells. Moreover, it has been shown that lipopolysaccharides do not induce the production of either IFN-α/β or IFN-λ in respiratory epithelial cells [18, 25] . The A549 cells used here are also a respiratory epithelial line, and lipopolysaccharide-induced MxA expression is not expected.

The biological activity of hIFN-λ1 was shown by RT-PCR. Increased MxA expression was shown in A549 cells treated for 10 hours with hIFN-λ1 (10 ng/ml) compared to control cells (Fig. 5a) . The level of MxA expression increased by more than 20-fold. Since MxA is an interferon-stimulated gene, increased expression can be considered reliable evidence of the biological activity of the obtained hIFN-λ1 [18] . Such an approach was also demonstrated [21] . It was shown that MxA is more inducible, in response to the action of hIFN-λ1, than oligoadenylate synthase (OAS), another canonical antiviral IGS.

The antiviral effect of IFN-λ has been shown in relation to various influenza A virus types [1, 7, 26, 27] . The action of IFN-λ1 leads to expression of a wide group of ISGs, which include such antiviral genes as MxA, OAS, and IFITM1 [28] . Thus, to confirm IFN-λ1 biological activity, the ability to suppress influenza A virus replication was assessed. Administration of exogenous IFN-λ1 led to a decrease in viral nucleoprotein levels in A549 cell supernatants (Fig. 5b) . We determined the concentration of interferon at which there was a two-fold decrease in viral load (EC50). At infectious doses of 0.004 moi and 0.016 moi, EC50 values were (11.0 ± 1.0) ng/ml and (9.1 ± 0.8) ng/ml, respectively (p = 0.05). Thus, close EC50 values were obtained for different infectious doses.

It should be noted that another group [21] also assessed the ability of recombinant IFN-λ1, and its synthetic analogs, to inhibit influenza A virus (H3N2 subtype) replication. The EC50 value for IFN-λ1 was about 1 ng/ml. The differences in EC50 values can be explained by the fact that susceptibility to interferon action varies significantly, depending on the subtype and strain of influenza A virus [29] . On the other hand, it is possible that not all IFN-λ1 molecules have the correct folding, and a certain fraction of the molecules may not have biological activity. However, the fact that a single product peak is observed on the chromatogram (Fig. 3b) indicates the presence of one isoform of the recombinant hIFN-λ1 in the sample. It is therefore potentially suitable for isolation of type III interferons not only for research and diagnostic applications, but also for therapeutic use. (G) 10 мМ sodium acetate, 5% trehalose, pH 5.5 12 Table 2 . Summary of all purification steps in physical values.

Step Comments: afrom 1 g wet weight pellet; bdetermined by Lowry method using lysozyme as standard protein; cbased on SDS-PAGE. d -Yield was determined based on total protein measurement (Lowry method) and densitometry of the target PAGE band; the amount of the target protein in cell lysate was designated as 100%.

J o u r n a l P r e -p r o o f 

Influenza virus activation of the interferon system

Impact and Regulation of Lambda Interferon Response in Human Metapneumovirus Infection

Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures

Pattern Recognition Receptors and the Innate Immune Response to Viral Infection

Human interferon-λ3 is a potent member of the type III interferon family

Interferon-λ in the Context of Viral Infections: Production, Response and Therapeutic Implications

Pathogenic potential of interferon αβ in acute influenza infection

Interferon-λ: Immune Functions at Barrier Surfaces and Beyond

Purification and characterization of recombinant human interleukin-29 expressed in Escherichia coli

On-column refolding purification and characterization of recombinant human interferon-λ1 produced in Escherichia coli

Homogeneous preparations of IL-28 and IL-29 -Patent US-7485701-B2 -PubChem

Expression, purification and characterization of human IFN-λ1 in Pichia pastoris

Purification, crystallization and preliminary crystallographic studies of the complex of interferon-λ1 with its receptor

The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity

IFNL1 -Interferon lambda-1 precursor -Homo sapiens (Human) -IFNL1 gene & protein

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

New Tricks: Influenza A Virus NS1 and In Vitro Fibrillogenesis

Mx GTPases: dynamin-like antiviral machines of innate immunity

Development of a multiplex quantitative PCR assay for the analysis of human cytokine gene expression in influenza A virus-infected cells

Antibody microarray immunoassay for screening and differential diagnosis of upper respiratory tract viral pathogens

Recombinant Human Interferon lambda-3(IFNL3) (Active) -Cusabio

Toll-Like Receptor Expression and Induction of Type I and Type III Interferons in Primary Airway Epithelial Cells

Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness

Disruption of Type III Interferon (IFN) Genes Ifnl2 and Ifnl3 Recapitulates Loss of the Type III IFN Receptor in the Mucosal Antiviral Response

The impact of the

Specificity and functional interplay between influenza virus PA-X and NS1 shutoff activity

Standardization of Human IL-29 (IFN-λ1): Establishment of a World Health Organization International Reference Reagent for IL-29 (IFN-λ1)